Covid-19 roundup: Pfizer, BioNTech forge ahead with enhanced vaccine; Brii moves on antibody to counter subvariants
While Pfizer and BioNTech’s Covid-19 vaccine has been one of the primary treatments so far in the pandemic, both companies are still adjusting and making improvements amidst the spread of the Omicron variant and its subvariants.
And now the latest step has come through. Both companies announced Wednesday that they have kicked off a Phase II study to evaluate an enhanced version of the vaccine candidate at a 30 µg dose level.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.